Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8001 vs lapatinib + capeccitabine in HER2-positive advanced breast cancer
CTR20180157Phase 3Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Feb 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BAT8001 in breast cancer, sponsored by Bio-Thera Solutions, Ltd.. Started Feb 2018; status: terminated.
02
Drugs
BAT8001
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20180157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180157.